Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey.
Atopic dermatitis
Disease burden
Eczema
Europe
Quality of life
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
10
12
2021
accepted:
16
02
2022
pubmed:
30
3
2022
medline:
30
3
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease that negatively impacts overall health, quality of life (QoL), and work productivity. Prior studies on AD burden by severity have focused on moderate-to-severe disease. Here, we describe the clinical and humanistic burden of AD in Europe across all severity levels, including milder disease. Data were analyzed from the 2017 National Health and Wellness Survey from adult respondents with AD in the EU-5 (France, Germany, Italy, Spain, and the UK). AD disease severity was defined based on self-reported assessments as "mild," "moderate," or "severe" and by Dermatology Life Quality Index (DLQI) severity bands. Self-reported outcomes for AD respondents by severity were assessed using propensity score matching. These outcomes included a wide range of selected medical/psychological comorbidities, overall QoL and functional status (EuroQol 5-Dimensions 5-Level and Short Form-36 version 2 questionnaires), and work productivity and activity impairment (Work Productivity and Activity Impairment questionnaire). In total, 4208 respondents with AD (mild AD, 2862; moderate AD, 1177; severe AD, 169) and 4208 respondents without AD were included in this analysis. Results showed greater burden across severity levels compared with matched non-AD controls. A higher proportion of respondents with mild-to-moderate AD, defined by DLQI severity bands, reported atopic comorbidities (P < 0.05) and a wide range of cardiac, vascular, and metabolic comorbidities, including hypertension, high cholesterol, angina, and peripheral vascular disease (P < 0.005), compared with non-AD controls. Relative to potential impacts of various medical and psychological burdens, respondents with mild-to-moderate AD reported higher activity impairment than controls (P < 0.0001). Clinical and humanistic burden was observed in European respondents with AD compared with matched non-AD controls across severity levels, with burden evident even in milder disease, highlighting the importance of improving disease management in early stages of AD.
Identifiants
pubmed: 35347660
doi: 10.1007/s13555-022-00700-6
pii: 10.1007/s13555-022-00700-6
pmc: PMC9021344
doi:
Types de publication
Journal Article
Langues
eng
Pagination
949-969Informations de copyright
© 2022. The Author(s).
Références
Br J Dermatol. 2012 Jun;166(6):1301-8
pubmed: 22372948
JAMA Dermatol. 2018 Aug 1;154(8):903-912
pubmed: 29971354
Am J Clin Dermatol. 2021 Jul;22(4):581-586
pubmed: 33725337
J Am Acad Dermatol. 2019 Jul;81(1):187-195
pubmed: 30905805
Allergy. 2015 Dec;70(12):1669-73
pubmed: 26289999
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242
Adv Ther. 2021 Mar;38(3):1627-1637
pubmed: 33555555
Am J Clin Dermatol. 2021 Jul;22(4):541-554
pubmed: 33954933
J Am Acad Dermatol. 2021 Oct;85(4):863-872
pubmed: 33957195
J Invest Dermatol. 2015 Jan;135(1):56-66
pubmed: 25078665
Curr Med Res Opin. 2016 Oct;32(10):1645-1651
pubmed: 27240604
Acta Derm Venereol. 2019 Jul 1;99(9):756-761
pubmed: 30896779
J Am Acad Dermatol. 2017 Aug;77(2):274-279.e3
pubmed: 28606711
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):958-964
pubmed: 33332697
Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611
pubmed: 34275122
Acta Paediatr. 2013 Jan;102(1):47-52
pubmed: 22994385
Curr Med Res Opin. 2018 Dec;34(12):2177-2185
pubmed: 29985061
J Am Acad Dermatol. 2016 Mar;74(3):491-8
pubmed: 26777100
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Dermatol Res Pract. 2009;2009:357046
pubmed: 20585477
Am J Clin Dermatol. 2020 Apr;21(2):275-284
pubmed: 32212104
Lancet. 2021 Jun 5;397(10290):2151-2168
pubmed: 34023008
J Allergy Clin Immunol Pract. 2013 Mar;1(2):142-51
pubmed: 24565453
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Acta Paediatr. 2017 Jan;106(1):75-80
pubmed: 27102081
Dermatol Ther (Heidelb). 2021 Jun;11(3):907-928
pubmed: 33846907
J Invest Dermatol. 2005 Oct;125(4):659-64
pubmed: 16185263
J Asthma Allergy. 2021 Jul 21;14:919-928
pubmed: 34321892
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Dtsch Dermatol Ges. 2021 Oct;19(10):1435-1442
pubmed: 34390128
Allergy. 2015 Jul;70(7):836-45
pubmed: 25832131
J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6
pubmed: 27417017
Allergy. 2006 May;61(5):556-62
pubmed: 16629784
Dermatol Ther (Heidelb). 2021 Feb;11(1):117-130
pubmed: 33180320
J Am Acad Dermatol. 2022 Jun;86(6):1335-1336.e18
pubmed: 35085682
Pediatr Allergy Immunol. 2008 Mar;19(2):125-31
pubmed: 18086231
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941